213 related articles for article (PubMed ID: 28981857)
1. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
Hopkins SC; Ogirala A; Loebel A; Koblan KS
Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
[TBL] [Abstract][Full Text] [Related]
2. Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.
Hopkins SC; Ogirala A; Loebel A; Koblan KS
Innov Clin Neurosci; 2017 Dec; 14(11-12):54-58. PubMed ID: 29410937
[TBL] [Abstract][Full Text] [Related]
3. Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM).
Hopkins SC; Ogirala A; Loebel A; Koblan KS
Psychiatry Res; 2020 Dec; 294():113569. PubMed ID: 33223272
[TBL] [Abstract][Full Text] [Related]
4. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
5. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Citrome L; Meng X; Hochfeld M
Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
Mosolov SN; Malyutin AV; Pikalov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(12):29-37. PubMed ID: 31994511
[TBL] [Abstract][Full Text] [Related]
10. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Stefanovics EA; Krystal JH; Rosenheck RA
Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
[TBL] [Abstract][Full Text] [Related]
11. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
[TBL] [Abstract][Full Text] [Related]
13. An excitement subscale of the Positive and Negative Syndrome Scale.
Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
Harvey RC; James AC; Shields GE
CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
[TBL] [Abstract][Full Text] [Related]
15. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
Kane JM; Assunção-Talbott S; Eudicone JM; Pikalov A; Whitehead R; Crandall DT
Schizophr Res; 2008 Oct; 105(1-3):208-15. PubMed ID: 18790605
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
19. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
[TBL] [Abstract][Full Text] [Related]
20. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Acta Psychiatr Scand; 2018 Nov; 138(5):420-431. PubMed ID: 30168131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
